The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

The viral hepatitis market has been on a steady growth path, evolving from $15.48 billion in 2023 to a projected $16.21 billion in 2024, with a Compound Annual Growth Rate (CAGR) of 4.7%. Looking ahead, the forecast is promising, anticipating further growth to reach $19.01 billion in 2028, driven by a CAGR of 4.1%. Let’s explore the factors contributing to this growth, the trends shaping the future, and the pivotal role of major players in the market.

The Root Cause: Elevated Prevalence of Hepatitis

• Hepatitis infection is a critical health concern
• Viruses A, B, C, D, and E contribute to liver inflammation and damage
• CDC reports a surge in hepatitis cases in the US in 2020
• Rising prevalence fuels the growth of the viral hepatitis market

Market Players: Driving Innovation and Drug Development

• Key players include Pfizer, Johnson & Johnson, F Hoffmann-La Roche, Merck & Co., AbbVie, Novartis, Sanofi, Bristol-Myers Squibb, Astra Zeneca, GlaxoSmithKline, Takeda Pharmaceutical, Gilead Sciences, Viatris, Teva Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Hetero Drugs, Eisai, Boehringer Ingelheim, Sun Pharmaceutical, Lupin Limited, Dr. Reddy’s Laboratories, Zydus Lifescience, Glenmark Pharmaceuticals, Cipla, Torrent Pharmaceuticals, Otsuka Pharmaceutical, Wockhardt

View More On The Viral Hepatitis Market Report 2023 –
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Innovations Driving Progress

• Companies focus on advancing new drugs
• Drug development and innovation boost scientific understanding
• Gilead Sciences Inc.’s Vemlidy gains FDA approval for pediatric use
• Gilead Sciences Inc. acquires MYR GmbH, expanding its HDV treatment portfolio

Strategic Moves: Gilead Sciences Inc.’s Acquisition

• Gilead Sciences Inc. acquires MYR GmbH for $1.60 billion
• Acquisition includes Hepcludex for treating chronic hepatitis delta virus (HDV)
• MYR GmbH, a German-based developer, enhances Gilead’s position in treating hepatitis B and D viral diseases

Market Segmentation: Insights for Precision

• Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
• Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis
• Treatment: Antiviral Drugs, Surgery, Vaccine, Immune Modulator Drugs, Other Treatments
• Route Of Administration: Oral, Parenteral, Other Routes Of Administration
• End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Region Dominance: North America Leading the Way

• North America emerges as the largest region in the viral hepatitis market in 2023
• Pioneering research, development, and technological advancements contribute to its leadership
• A key contributor to the market’s robust growth

Request A Sample Of The Global Viral Hepatitis Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=13028&type=smp

The Viral Hepatitis Global Market Report 2023  provides a comprehensive overview on the viral hepatitis market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Fatty Liver Treatment Global Market Report 2023
Oncolytic Virus Therapy Global Market Report 2023
Herpes Simplex Virus Treatment Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model